Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis
EV exhibited real-world efficacy in Japanese mUC patients comparable to the eligible patients' outcomes in the EV-301 trial. Ineligible patients showed statistically inferior outcomes.
Authors
- Hiroko Sato (ORCID: https://orcid.org/0000-0002-7139-7792)
- Kotaro Suzuki (ORCID: https://orcid.org/0000-0002-4692-2970)
- Ichiro Yonese (ORCID: https://orcid.org/0009-0001-2607-1013)
- Naoko Kawamura (ORCID: https://orcid.org/0000-0001-9517-7543)
- Keita Izumi (ORCID: https://orcid.org/0000-0002-9785-6432)
- Noboru Numao
- Saori Araki
- Takanobu Yamamoto
- Sho Uehara
- Atsushi Yoshinaga
- Masahiro Toide
- Masaharu Inoue
- Hitoshi Masuda
- Ryoji Takazawa
- Hiroshi Fukushima
- Yasuhisa Fujii
- Hajime Tanaka
- Shugo Yajima
- Wei Chen
- Yuki Nakamura
- Akihiro Hirakawa
- Soichiro Yoshida
Institutions
- Tokyo Medical and Dental University (JP)
- Tokyo Metropolitan Ohtsuka Hospital (JP)
- Tsuchiura Kyodo General Hospital (JP)
- Showa General Hospital (JP)
- JA Toride Medical Center (JP)
- Saitama Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- Dokkyo Medical University Saitama Medical Center (JP)
- National Cancer Center Hospital East (JP)
- Kohnan Hospital (JP)
- Saitama Red Cross Hospital (JP)
- Tokyo Metropolitan Tama Medical Center (JP)
- Soka Municipal Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1093/jjco/hyag012
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00